Document:

<PAGE>
EXHIBIT 10.89

                                ANDRX CORPORATION

                      RESTRICTED STOCK UNIT AWARD AGREEMENT

      This Restricted Stock Unit Award Agreement ("Agreement") is entered into
as of February 27, 2004 between Andrx Corporation, a Delaware corporation
(including any of its subsidiaries or affiliates, the "Company") and Thomas P.
Rice ("Employee"), pursuant to the Company's 2000 Stock Option Plan, as amended
and restated (the "2000 Plan"). Except as defined herein, capitalized terms
shall have the meaning ascribed to them under the employment agreement between
the Company and the Employee dated as of February 27, 2004 (as now written or
hereafter amended, the "Employment Agreement").

      1.    Award of Restricted Stock Units. The Company hereby awards to the
Employee as of the date first written above ("Date of Grant"), an award of
40,000 restricted stock units (each an "RSU"), with each RSU representing the
right to acquire one share of Andrx Corporation - Andrx Group Common Stock, par
value $.001 ("Common Stock"), subject to the conditions, restrictions and
limitations set forth below (the "RSU Award"). The Employee hereby acknowledges
and accepts such grant and agrees to acquire the RSU Award and the shares of
Common Stock covered thereby upon such terms and subject to such conditions,
restrictions and limitations as provided herein.

      2.    Vesting.

            (a)   Subject to Sections 2(b) and 3, Employee shall become vested
in 33 1/3% of the RSUs covered by the RSU Award on each of the 1st, 2nd and 3rd
anniversaries of the Date of Grant, thereby causing such RSU to become "Vested
RSUs".

            (b)   Notwithstanding Sections 2(a) and 3, Employee shall become
vested in any or all RSUs covered by the RSU Award as of such earlier date or
dates as may be expressly determined by the Company's Board of Directors or its
Compensation Committee (in either case, the "Compensation Committee"), in its
sole discretion, or as required pursuant to the Employment Agreement.

      3.    Effect of Certain Events Upon Vesting.

            (a)   If Employee's employment with the Company is terminated by the
Company prior to all RSUs becoming Vested RSUs pursuant to Section 2 above, and
Cause (as hereinafter defined) exists, then (i) all RSUs, and any shares
underlying such RSUs, which have not previously been transferred to or sold by
Executive (including Vested RSUs) shall immediately be forfeited, without any
payment of consideration by the Company to the Employee, unless expressly
determined otherwise by the Compensation Committee in its sole discretion, and
(ii) to the extent the Employee derived any benefit from the sale, transfer,
receipt or otherwise of any Vested RSUs within the twelve month period prior to
the occurrence of Cause, unless expressly determined otherwise by the
Compensation Committee in its sole discretion, the Employee shall be liable to
the Company for an amount equal to the amount realized (or the payment received)
by Employee as a result thereof, net of any income
<PAGE>
taxes actually paid by Employee with respect thereto. Such damages amount is in
addition to, and not in lieu of, any other remedy or recourse to which Andrx may
be entitled.

            (b)   "Cause" shall mean (i) Employee's conviction of, or plea of
nolo contendere to a felony involving a crime of moral turpitude; (ii)
Employee's having been found guilty, by a court of competent jurisdiction, of
the commission of any willful or fraudulent act that is adverse to the interests
of Company, or (iii) Employee's breach, either prior to the termination of
employment or thereafter, of this agreement or the Confidentiality and
Non-Competition Agreement attached hereto as EXHIBIT A (which is incorporated
herein by reference).

            (c)   If the Company terminates the Employee pursuant to 6(b) of the
Employment Agreement or if the Employee terminates his employment pursuant to
6(d) of the Employment Agreement, then upon execution of the release attached
hereto as EXHIBIT B (which is incorporated herein by reference), all RSUs shall
immediately become Vested RSUs (unless Section 3(a) applies).

      4.    Delivery of Shares.

            (a)   As soon as practicable following an RSU becoming a Vested RSU,
the Company shall deliver to the Employee one share of Common Stock for each
Vested RSU.

            (b)   In order to mitigate any loss of deduction under Section
162(m) of the Internal Revenue Code, the Company may elect to defer the
Employee's receipt of the shares of Common Stock upon the vesting of any RSUs to
no later than the date 10 days after the Employee's employment with the Company
terminates for any reason, so long as the Employee agrees to such deferral, with
such agreement not to be unreasonably withheld. The Employee is not obligated to
incur any economic loss to effect such mitigation.

      5.    Restrictions on Transfer. The RSU Award granted hereunder to the
Employee may not be sold, assigned, transferred, pledged or otherwise
encumbered, whether voluntarily or involuntarily, by operation of law or
otherwise; provided, however, that the RSU Award and/or any Vested RSUs shall be
transferable by the Employee, in whole or in part, to members of his immediate
family, to trusts or partnerships formed exclusively for the benefit of the
Employee and/or members of his immediate family, or pursuant to a domestic
relations order in settlement of marital property rights. Except as permitted by
the foregoing, no right or benefit under this Agreement shall be subject to
transfer, anticipation, alienation, sale, assignment, pledge, encumbrance or
charge, whether voluntary, involuntary, by operation of law or otherwise, and
any attempt to transfer, anticipate, alienate, sell, assign, pledge, encumber or
charge the same shall be void. No right or benefit hereunder shall in any manner
be liable for or subject to any debts, contracts, liabilities or torts of the
person entitled to such benefits. Any assignment in violation of this Section 5
shall be void.

      6.    Withholding Tax Requirements. For purposes of tax withholding, the
Company shall withhold shares of Common Stock at the time Common Stock is
delivered (or otherwise becomes taxable) to the Employee, and shall pay only the
statutory minimum withholding amounts to the applicable tax authorities in
accordance therewith.

                                       2
<PAGE>
      7.    Sale and Issuance of Common Stock. The Employee agrees that he/she
shall not sell any Common Stock delivered to him/her pursuant to this Agreement
and that the Company shall not be obligated to deliver any shares of Common
Stock if counsel to the Company reasonably determines that such sale or delivery
would violate any applicable law or any rule or regulation of any governmental
authority or any rule or regulation of, or agreement of the Company with, any
securities exchange or association upon which the Common Stock is listed or
quoted. The Company shall be obligated to take all reasonable action in order to
cause the delivery of shares of Common Stock to comply with any such law, rule,
regulation or agreement.

      8.    Limitation of Rights. Nothing contained in this Agreement, and no
action of the Company with respect hereto, shall confer or be construed to
confer on the Employee any right to continue in the employment or service of the
Company, or affect the right of the Company to terminate the employment or
service of the Employee at any time for any reason.

      9.    No Interest in Company Assets. The Employee shall not have any
interest in any fund or specific asset of the Company by reason of this RSU
Award.

      10.   No Rights as a Stockholder Prior to Delivery. The Employee shall not
have any right, title or interest in, or be entitled to vote or receive
distributions in respect of, or otherwise be considered the owner of, any of the
shares of Common Stock covered by the RSU Award, except to the extent that such
shares are Vested RSUs, whether or not delivered to the Employee.

      11.   Adjustment. The RSU Award shall be subject to adjustment (including,
without limitation, as to the number of shares of Common Stock covered by the
RSU Award) in the reasonable discretion of the Compensation Committee in such
manner as the Compensation Committee may deem equitable and appropriate if there
shall be any increase or decrease in the number of issued and outstanding shares
of Common Stock through the declaration of a stock dividend or through any
recapitalization resulting in a stock split, combination or exchange of shares
(other than any such exchange or issuance of shares through which shares are
issued to effect an acquisition of another business or entity or the Company's
purchase of shares to exercise a "call" purchase option). Except as otherwise
expressly provided herein, the issuance by the Company of shares of its capital
stock of any class, or securities convertible into or exchangeable for shares of
its capital stock of any class, either in connection with a direct or unwritten
sale or upon the exercise of rights or warrants to subscribe therefore or
purchase such shares, or upon conversion of obligations of the Company
convertible into such shares or other securities, shall not affect, and no
adjustment by reason thereof shall be made with respect to this RSU Award.

      12.   Miscellaneous Provisions. For purposes of this Agreement, the
following miscellaneous provisions shall be applicable:

            (a)   Company Disclosure. The Employee acknowledges and agrees that
the Company, its stockholders and/or its directors and officers have no duty or
obligation to disclose to the Employee any material information regarding the
business of the Company or affecting the value of Common Stock at any time while
the Employee is employed by the Company or any of its subsidiaries and at any
time following the termination of the Employee's employment with the Company or
any of its subsidiaries, including without limitation, any information

                                       3
<PAGE>
concerning plans for the Company to make a public offering of its securities or
to be acquired by or merged with or into another firm or entity.

            (b)   Successors and Assigns. This Agreement shall bind and inure to
the benefit of and be enforceable by the Employee, the Company and their
respective permitted successors and assigns (including personal representatives,
heirs and legatees), except that the Employee may not assign any rights or
obligations under this Agreement, except to the extent and in the manner
expressly permitted herein.

            (c)   Notices. Any notice under this Agreement to the Company or to
the Employee shall be addressed as follows:

            If to the Company:

            8151 Peters Road
            Plantation, FL 33324
            Attention: General Counsel

            If to Employee:

            At the address listed on the signature page

            (d)   Severability. If any provision of this Agreement for any
reason should be found by any court of competent jurisdiction to be invalid,
illegal or unenforceable, in whole or in part, such declaration shall not affect
the validity, legality or enforceability of any remaining provision or portion
thereof, which remaining provision or portion thereof shall remain in full force
and effect as if this Agreement had been adopted with the invalid, illegal or
unenforceable provision or portion thereof eliminated.

            (e)   2000 Stock Option Plan. This Agreement is entered into
pursuant to the 2000 Plan, a copy of which has been provided to Employee.
Employee acknowledges that Employee has received and reviewed the 2000 Plan.
Unless specifically set forth in this Agreement to the contrary, this Agreement
shall remain subject to all the provisions of the 2000 Plan, and in the event
there are any inconsistencies by and among this Agreement and the 2000 Plan, the
Employee and/or the Company shall first be bound by the terms of this Agreement,
then the 2000 Plan.

            (f)   Amendment. The Company may amend or modify this Agreement at
any time by mutual agreement between the Company and Employee (or such other
persons as may then have an interest therein). In addition, by mutual agreement
between the Company and Employee (or such other persons as may then have an
interest therein), Employee may be granted an award in substitution and exchange
for, and in cancellation of, the RSU Award under any other present or future
plan of the Company or any present or future plan of an entity which (i) is
purchased by the Company, (ii) purchases the Company, or (iii) merges into or
with the Company; provided, however, that such substitution, exchange and/or
cancellation does not increase the accounting charge-to-earnings originally
expensed by the Company with respect to the RSU Award.

                                       4
<PAGE>
            (g)   Headings. The headings, captions and arrangements utilized in
this Agreement shall not be construed to limit or modify the terms or meaning of
this Agreement.

            (h)   Arbitration. Any disputes arising out of or in connection with
this Agreement or any of its provisions, including but not limited to the
alleged breach of the provisions of this Agreement, shall be submitted to and
determined by arbitration conducted in accordance with the Rules of the American
Arbitration Association. The award rendered by the Arbitrator may be entered as
a judgment (with full binding, force and effect) in any court having
jurisdiction thereof. This Agreement shall constitute a written agreement to
submit any such dispute or controversy to arbitration within the meaning of the
Florida Arbitration Code and shall confer jurisdiction on the Courts of the
State of Florida to enforce such agreement to arbitrate and to enter judgment on
an award in accordance with said Florida Arbitration Code.

            (i)   Governing Law. This Agreement shall be governed by and
construed in accordance with the internal laws of the State of Florida. Any
arbitration, lawsuits or other proceedings related to this Agreement or the
transactions herein described shall be commenced and held in Dade or Broward
County, Florida.

            (j)   Determinations by Compensation Committee. All references in
this Agreement to determinations to be made by the Compensation Committee shall
be deemed to include determinations by any person or persons to whom the
Compensation Committee may delegate such authority in accordance with the rules
adopted thereby.

                                       5
<PAGE>
            (k)   Validity of Agreement. This Agreement shall be valid and
binding only if and when it has been duly executed by an officer of the Company
(which may be in facsimile signature) and by Employee.

      IN WITNESS WHEREOF, this Restricted Stock Unit Award Agreement has been
executed as of the date first written above.

EMPLOYEE:                               ANDRX CORPORATION

By:                                     By:
   ------------------------------             ----------------------------------
   Thomas P. Rice                             Angelo C. Malahias, President

Employee Address:

----------------------------

----------------------------

----------------------------

                                       6
<PAGE>
EXHIBIT A

                                ANDRX CORPORATION
                  CONFIDENTIALITY AND NON-COMPETITION AGREEMENT

                                       7
<PAGE>
EXHIBIT B

                                ANDRX CORPORATION
                                 FORM OF RELEASE

                                       8<PAGE>
                                                                   EXHIBIT 10.90

                    AMENDMENT NO. 1 TO TERMINATION AGREEMENT

         This Amendment No. 1 to the Termination Agreement (this "AMENDMENT NO.
1"), is dated as of January 17, 2005, by and among Andrx Laboratories (NJ),
Inc., a Delaware corporation as the owner of all the assets and liabilities of
the company formerly known as Andrx Labs, Inc., Andrx Pharmaceuticals, Inc., a
Florida corporation, and Anda, Inc., a Florida corporation, each of which is a
subsidiary of Andrx Corporation ("ANDRX"), and Sandoz Inc. (f.k.a. Geneva
Pharmaceuticals, Inc.), a Colorado corporation ("SANDOZ"). Andrx and Sandoz are
sometimes referred to collectively herein as the "PARTIES" or singly as a
"PARTY".

         WHEREAS, the Parties entered into a Termination Agreement as of October
24, 2001 (the "TERMINATION AGREEMENT"), in termination of a Product
Distribution, Development and Licensing Agreement which had been executed as of
May 1, 1999 (the "LICENSING AGREEMENT"), in order to terminate the Licensing
Agreement and allocate the rights and responsibilities of the parties
post-termination; and

         WHEREAS, the Parties desire to amend the Termination Agreement to
clarify certain issues.

         NOW, THEREFORE, it is hereby agreed as follows:

         1. The first sentence of paragraph 2 of Section 2B. of the Termination
Agreement is hereby deleted in its entirety and replaced with the following:

                  "In addition to the payments set forth on Exhibit A-1, Andrx
shall pay to Sandoz the Andrx Payments in accordance with the schedule attached
hereto as Amendment No. 1 to Exhibit A-2."

         2. Exhibit A-2, shall be deleted and replaced in its entirety with the
Amendment No. 1 to Exhibit A-2 attached hereto, which Amendment No. 1 to Exhibit
A-2 shall be effective as of the first Commercial Sale by Andrx of the Metformin
extended-release product known as Fortamet(TM)in the United States.

         3. All capitalized terms used and not otherwise defined in this
Amendment No. 1 shall have the meanings as set forth in the Agreement.

         4. This Amendment No. 1 may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Signatures to this Amendment No. 1 may
be transmitted via facsimile and such signatures shall be deemed to be
originals.

                            [SIGNATURE PAGE FOLLOWS]

                                       1

Filed under application for confidential treatment.

<PAGE>

         IN WITNESS WHEREOF, the Parties hereto have caused this Amendment No. 1
to the Termination Agreement to be duly executed by their respective authorized
officers as of the day and year first above written.

ANDRX LABORATORIES (NJ), INC.               ANDA, INC.

By:  ____________________________           By:  ____________________________
         Name:                                       Name:
         Title:                                      Title:

ANDRX PHARMACEUTICALS, INC.                 SANDOZ INC.

By:  ___________________________            By:  ____________________________
         Name:                                       Name:
         Title:                                      Title:

                                       2

Filed under application for confidential treatment.

<PAGE>

                         AMENDMENT NO. 1 TO EXHIBIT A-2

         Andrx shall owe to Sandoz an annual payment (the "ANDRX PAYMENT"),
payable to Sandoz on a quarterly basis. Such payment shall be subject to the
Minimum and Maximum amounts listed below for each particular Year (listed
below), and otherwise shall be [xxxx]* of Net Sales of the Metformin extended
release product known as Fortamet(TM) (the "PRODUCT") in the United States for
such Year. The Quarterly Share of the Andrx Payment, along with appropriate
supporting documentation, shall be payable by Andrx to Sandoz within forty-five
(45) days after the end of each calendar quarter, for a term of five (5) years,
in accordance with the schedule below. For purposes of this Amendment, the term
"Quarterly Share" shall mean the lesser of [xxxx]* of Net Sales or the Maximum
(as set forth in the schedule below) provided, however that in any particular
year Sandoz shall not be paid any amount in excess of the Maximum for such
particular year. Within 45 days of the end of a particular year, Andrx shall
remit to Sandoz the difference between the Minimum and [xxxx]* of Net Sales for
that particular year if the [xxxx]* of Net Sales is less than the Minimum. For
example, in Year 1 if [xxxx]* of the Net Sales were $2,500,000, then Andrx would
remit $125,000 within 45 days of the end of Year 1. If in Year 2 [xxxx]* of Net
Sales were $11,000,000, then Andrx would have remitted up to $10,000,000 to
Sandoz during Year 2, but would not have paid any amounts in excess of
$10,000,000.

<TABLE>
<CAPTION>

                   Term                                                      Annual Andrx Payment
----------------------------------------                     -------------------------------------------------------
<S>                                                          <C>
*Year 1:  May 12, 2004 to March 31, 2005                     A Minimum of $2,625,000 and a Maximum of $9,625,000

Year 2:  April 1, 2005 to March 31, 2006                     A Minimum of $4,000,000 and a Maximum of $10,000,000

Year 3:  April 1, 2006 to March 31, 2007                     A Minimum of $5,000,000** and a Maximum of $10,000,000

Year 4:  April 1, 2007 to March 31, 2008                     A Minimum of $5,000,000** and a Maximum of $10,000,000

*Year 5:  April 1, 2008 to May 11, 2009                      A Minimum of $5,375,000** and a Maximum of $10,375,000

</TABLE>

* Note: Andrx hereby represents that May 12, 2004 was the date of first
Commercial Sale. Pursuant to the above table, Year 1 shall be reduced to less
than 1 calendar year by reducing the period from May 12, 2004 through June 30,
2005 to May 12, 2004 through March 31, 2005, and Year 5 shall be extended
correspondingly pursuant to the above table. This will result in a total of 21
quarterly payments, with the initial quarterly payment due within 45 days after
June 30, 2004, and the final quarterly payment due within 45 days after May 11,
2009.

** Note: If a third party is selling an FDA approved AB-rated generic version of
the Product (the "GENERIC PRODUCT") in Year 3, Year 4, or Year 5, and such
Generic Product is not (i) an "authorized generic" of Andrx's Product or (ii)
based on an FDA Abbreviated New Drug Application developed or filed by Andrx, an
Affiliate or sublicensee thereof (provided however that (ii) shall not apply if
through a merger or sale of substantially all of the entity's assets Andrx
acquires an entity that developed an FDA approved AB-rated generic version of
the Product); then the Minimum in such Years shall be reduced by $2,000,000 in
any such Year 3 or Year 4 during which the Generic Product is being sold, and by
$2,187,500 in Year 5 during which the Generic Product is being sold. An
"AFFILIATE" shall mean a company controlled by, controlling, or under common
control with a Party.

                                       1

* Filed under application for confidential treatment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]